The wide-open field for Trump’s FDA commissioner announcement stems from the agency’s leadership vacuum following Marty Makary’s May 2026 resignation, leaving it under acting direction amid ongoing regulatory reform priorities. Contenders such as Stephen Hahn, Sara Brenner, and Kyle Diamantas bring distinct profiles—prior FDA leadership experience, clinical or oncology expertise, and White House policy roles—that differentiate them on confirmation prospects and alignment with administration goals on drug approval timelines and agency structure. Factors that could consolidate support include final White House vetting outcomes, Senate dynamics on confirmation votes, and any late shifts in domestic policy council recommendations before a public announcement, which the market currently prices as highly likely by year-end.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateStephen Hahn <1%
Kyle Diamantas <1%
Sara Brenner <1%
No announcement by December 31 <1%
$33,305 Vol.
$33,305 Vol.
Dec 30, 2026
Kyle Diamantas
1%
Stephen Hahn
1%
Brett Giroir
<1%
Grace Graham
<1%
Sara Brenner
1%
No announcement by December 31
<1%
Stephen Hahn <1%
Kyle Diamantas <1%
Sara Brenner <1%
No announcement by December 31 <1%
$33,305 Vol.
$33,305 Vol.
Dec 30, 2026
Kyle Diamantas
$6,786 Vol.
1%
Stephen Hahn
$4,144 Vol.
1%
Brett Giroir
$5,265 Vol.
<1%
Grace Graham
$6,683 Vol.
<1%
Sara Brenner
$7,418 Vol.
1%
No announcement by December 31
$3,007 Vol.
<1%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The wide-open field for Trump’s FDA commissioner announcement stems from the agency’s leadership vacuum following Marty Makary’s May 2026 resignation, leaving it under acting direction amid ongoing regulatory reform priorities. Contenders such as Stephen Hahn, Sara Brenner, and Kyle Diamantas bring distinct profiles—prior FDA leadership experience, clinical or oncology expertise, and White House policy roles—that differentiate them on confirmation prospects and alignment with administration goals on drug approval timelines and agency structure. Factors that could consolidate support include final White House vetting outcomes, Senate dynamics on confirmation votes, and any late shifts in domestic policy council recommendations before a public announcement, which the market currently prices as highly likely by year-end.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Binuksan ang Market: May 12, 2026, 7:59 PM ET
Volume
$33,305Petsa ng Pagtatapos
Dec 31, 2026Binuksan ang Market
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The wide-open field for Trump’s FDA commissioner announcement stems from the agency’s leadership vacuum following Marty Makary’s May 2026 resignation, leaving it under acting direction amid ongoing regulatory reform priorities. Contenders such as Stephen Hahn, Sara Brenner, and Kyle Diamantas bring distinct profiles—prior FDA leadership experience, clinical or oncology expertise, and White House policy roles—that differentiate them on confirmation prospects and alignment with administration goals on drug approval timelines and agency structure. Factors that could consolidate support include final White House vetting outcomes, Senate dynamics on confirmation votes, and any late shifts in domestic policy council recommendations before a public announcement, which the market currently prices as highly likely by year-end.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$33,305Petsa ng Pagtatapos
Dec 31, 2026Binuksan ang Market
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...The wide-open field for Trump’s FDA commissioner announcement stems from the agency’s leadership vacuum following Marty Makary’s May 2026 resignation, leaving it under acting direction amid ongoing regulatory reform priorities. Contenders such as Stephen Hahn, Sara Brenner, and Kyle Diamantas bring distinct profiles—prior FDA leadership experience, clinical or oncology expertise, and White House policy roles—that differentiate them on confirmation prospects and alignment with administration goals on drug approval timelines and agency structure. Factors that could consolidate support include final White House vetting outcomes, Senate dynamics on confirmation votes, and any late shifts in domestic policy council recommendations before a public announcement, which the market currently prices as highly likely by year-end.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong